Clinical trials (STEP programme) have demonstrated that Wegovy can lead to significant weight losstypically 1015% of initial body weight over 68 weekswhen combined with lifestyle modifications, though individual responses vary
While the fluorescent dye CMFDA labelled several other cysteine-containing proteins in the proteome, C1-27 showed a selective inhibition of the GSTO1 band up to 1 M (Fig
Federici M, Porzio O, Zucaro L, Giovannone B, Borboni P, Marini MA, Lauro D, Sesti G
Bartal A, Matrai Z, Szucs A, Liszkay G
Integrative Medicine (Encinitas, Calif.) , 13(1), 812
Newer agents like tirzepatide (a dual GLP-1/GIP receptor agonist) offer enhanced efficacy if semaglutide alone hasn't met your goals, but this represents optimization rather than discontinuation